Bessemer Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.94M Buy
64,184
+5,812
+10% +$814K 0.01% 351
2025
Q4
$7.17M Buy
58,372
+5,409
+10% +$657K 0.01% 364
2025
Q3
$5.88M Buy
52,963
+2,145
+4% +$244K 0.01% 348
2025
Q2
$5.63M Sell
50,818
-4,177
-8% -$445K 0.01% 349
2025
Q1
$6.16M Sell
54,995
-42,172
-43% -$4.35M 0.01% 333
2024
Q4
$8.97M Buy
97,167
+9,573
+11% +$862K 0.01% 319
2024
Q3
$7.34M Sell
87,594
-33,908
-28% -$2.59M 0.01% 346
2024
Q2
$8.34M Buy
121,502
+430
+0.4% +$28.7K 0.01% 325
2024
Q1
$8.87M Buy
121,072
+23,213
+24% +$1.78M 0.02% 322
2023
Q4
$7.93M Buy
97,859
+5,992
+7% +$466K 0.02% 327
2023
Q3
$6.88M Buy
91,867
+26,381
+40% +$2.03M 0.02% 315
2023
Q2
$5.05M Buy
65,486
+4,482
+7% +$357K 0.01% 357
2023
Q1
$5.06M Sell
61,004
-320
-0.5% -$26.5K 0.01% 339
2022
Q4
$5.26M Sell
61,324
-1,471
-2% -$116K 0.01% 324
2022
Q3
$3.87M Buy
62,795
+9,609
+18% +$606K 0.01% 349
2022
Q2
$3.29M Sell
53,186
-4,404
-8% -$273K 0.01% 364
2022
Q1
$3.42M Buy
57,590
+11,356
+25% +$726K 0.01% 280
2021
Q4
$3.36M Sell
46,234
-7,773
-14% -$535K 0.01% 278
2021
Q3
$3.77M Buy
54,007
+1,423
+3% +$100K 0.01% 262
2021
Q2
$3.62M Buy
52,584
+2,046
+4% +$137K 0.01% 271
2021
Q1
$3.27M Buy
50,538
+3,932
+8% +$254K 0.01% 279
2020
Q4
$2.71M Sell
46,606
-2,169
-4% -$131K 0.01% 277
2020
Q3
$3.08M Sell
48,775
-24,841
-34% -$1.72M 0.01% 278
2020
Q2
$5.66M Buy
73,616
+29,752
+68% +$2.28M 0.02% 279
2020
Q1
$3.28M Buy
43,864
+1,218
+3% +$84.2K 0.01% 340
2019
Q4
$2.77M Sell
42,646
-710
-2% -$46.2K 0.01% 476
2019
Q3
$2.75M Buy
43,356
+9,412
+28% +$615K 0.01% 431
2019
Q2
$2.29M Buy
33,944
+620
+2% +$40.8K 0.01% 488
2019
Q1
$2.17M Sell
33,324
-3,780
-10% -$251K 0.01% 436
2018
Q4
$2.32M Buy
37,104
+6,487
+21% +$453K 0.01% 342
2018
Q3
$2.36M Sell
30,617
-967
-3% -$73K 0.01% 351
2018
Q2
$2.24M Sell
31,584
-4,057
-11% -$286K 0.01% 378
2018
Q1
$2.69M Sell
35,641
-4,392
-11% -$349K 0.01% 355
2017
Q4
$2.87M Sell
40,033
-1,299,509
-97% -$98.7M 0.01% 349
2017
Q3
$109M Sell
1,339,542
-521,186
-28% -$39.9M 0.43% 93
2017
Q2
$132M Sell
1,860,728
-700,374
-27% -$46.6M 0.53% 76
2017
Q1
$174M Buy
2,561,102
+11,806
+0.5% +$830K 0.73% 47
2016
Q4
$183M Buy
2,549,296
+541,711
+27% +$40.3M 0.84% 27
2016
Q3
$159M Buy
2,007,585
+469,075
+30% +$38.1M 0.8% 33
2016
Q2
$128M Sell
1,538,510
-176,838
-10% -$15.7M 0.7% 40
2016
Q1
$158M Sell
1,715,348
-224,683
-12% -$20.3M 0.89% 25
2015
Q4
$196M Buy
1,940,031
+60,001
+3% +$6.24M 1.09% 19
2015
Q3
$185M Buy
1,880,030
+33,331
+2% +$3.7M 1.06% 20
2015
Q2
$216M Sell
1,846,699
-292,285
-14% -$31.9M 1.13% 13
2015
Q1
$210M Buy
2,138,984
+996,416
+87% +$101M 1.06% 20
2014
Q4
$108M Buy
1,142,568
+1,111,415
+3,568% +$115M 0.58% 72
2014
Q3
$3.32M Sell
31,153
-693
-2% -$67.9K 0.02% 293
2014
Q2
$2.64M Buy
31,846
+3,889
+14% +$303K 0.02% 307
2014
Q1
$1.98M Sell
27,957
-958,535
-97% -$75.2M 0.01% 344
2013
Q4
$74.1M Buy
986,492
+2,110
+0.2% +$147K 0.53% 73
2013
Q3
$61.9M Sell
984,382
-34,490
-3% -$2.06M 0.5% 76
2013
Q2
$52.2M Buy
+1,018,872
New +$53.1M 0.47% 87

Other funds holding GILD

Bessemer Group's GILD Position: Q1 2026 in Review

Bessemer Group increased its Gilead Sciences (GILD) stake by 10% in Q1 2026, buying an estimated $814K and bringing the position to 64,184 shares worth $8.94M. The position accounts for 0.01% of the portfolio, ranked #351.

Bessemer Group first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $216M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Bessemer Group held 64,184 shares of Gilead Sciences worth $8.94M as of Q1 2026.
  • Bessemer Group bought 5,812 Gilead Sciences shares in Q1 2026, an estimated $814K.
  • Gilead Sciences made up 0.01% of Bessemer Group's portfolio in Q1 2026, its #351 holding.
  • Bessemer Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Bessemer Group's Gilead Sciences position peaked at $216M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.